... the drug is expected to have annual sales of $6.03 billion by 2016. With a strong pipeline of drugs treating HIV/AIDS, liver disease, cardiovascular, and respiratory diseases already on the market, and with roughly thirty indications in various ...
http://seekingalpha.com/article/1859561-gilead-and-abbvie-battle-for-top-spot-in-20-billion-hepatitis-drug-market?source=feed
http://seekingalpha.com/article/1859561-gilead-and-abbvie-battle-for-top-spot-in-20-billion-hepatitis-drug-market?source=feed
No comments:
Post a Comment